{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:23:55Z","timestamp":1760549035329,"version":"3.41.2"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1111\/igc.0b013e3181e94331","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T14:29:09Z","timestamp":1291386549000},"page":"1132-1136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Pilot Study Evaluating a Novel Regimen Comprised of Carboplatin, Paclitaxel, and Bevacizumab for Advanced-Stage Ovarian Carcinoma"],"prefix":"10.1016","volume":"20","author":[{"suffix":"III","given":"John V.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Micha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Rettenmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa N.","family":"Abaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina L.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram H.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181e94331_bb0005","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0010","first-page":"2099","article-title":"A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer","volume":"85","author":"Shen","year":"2005","journal-title":"Zhonghua Yi Xue Za Zhi."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.04.008","article-title":"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma","volume":"114","author":"Safra","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0020","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0090-8258(03)00337-8","article-title":"Gynecologic Oncology Group Protocol GOG 182-ICON5. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5","volume":"90","author":"Copeland","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1525-1438.2007.00886.x","article-title":"A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"17","author":"Micha","year":"2007","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2009.22.7900","article-title":"Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as f irst-line chemotherapy for advanced mullerian tumors","volume":"28","author":"Penson","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2009.08.032","article-title":"Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer","volume":"115","author":"Hurt","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0045","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0050","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-007-0466-z","article-title":"Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO","volume":"61","author":"Sehouli","year":"2008","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0060","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0090-8258(03)00337-8","article-title":"Gynecologic Oncology Group Protocol GOG 182-ICON5. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5","volume":"90","author":"Copeland","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0065","first-page":"31","article-title":"Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer","volume":"27","author":"Vergote","year":"2000","journal-title":"Semin Oncol."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0070","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0075","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Creatinine clearance: bedside estimate","volume":"79","author":"Jelliffe","year":"1973","journal-title":"Ann Intern Med."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0085","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-03-0787","article-title":"Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer","volume":"10","author":"Rustin","year":"2004","journal-title":"Clin Cancer Res."},{"year":"2003","series-title":"Common Terminology Criteria for Adverse Events (Version 3.0)","author":"National Institute of Health","key":"10.1111\/IGC.0b013e3181e94331_bb0090"},{"key":"10.1111\/IGC.0b013e3181e94331_bb0095","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0959-8049(02)00242-3","article-title":"Dose dense cisplatin\/paclitaxel: a well tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer","volume":"38","author":"de Jongh","year":"2002","journal-title":"Eur J Cancer."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0100","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.ejca.2005.04.005","article-title":"RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma","volume":"41","author":"Therasse","year":"2005","journal-title":"Eur J Cancer."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0105","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1471-2407-9-246","article-title":"Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer","volume":"9","author":"Hong","year":"2009","journal-title":"BMC Cancer."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology."},{"key":"10.1111\/IGC.0b013e3181e94331_bb0115","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2005.05.1573","article-title":"Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181e94331","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24037265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24037265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:34:42Z","timestamp":1753223682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24037265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S1048891X24037265"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181e94331","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pilot Study Evaluating a Novel Regimen Comprised of Carboplatin, Paclitaxel, and Bevacizumab for Advanced-Stage Ovarian Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181e94331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}